With this focused attention from management, the consumer-health spin-off enjoyed a relatively smooth path to independence and a successful public listing. Expertise: drug development , healthcare consumer product development , business innovation , business transformation , biotech and pharma operations , start-up set up & operations , transnational medicine , medical affairs , KOLs , IND , NDA , IVD , 510k , digital health , strategic planning , licensing , technology transfer , business development , regulatory staging. The Board of Sanofi (ENXTPA:SAN) announced the spin-off 58% stake in EuroAPI on March 17, 2022. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Scotland Health Tech privacy policy. However, it looks like that les grandes manoeuvres, aimed at the realization of this project, will proceed at a slow speed. Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA. 5. Sanofi is a long-term player. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . Partnered with business leaders to facilitate the Retired after 24+ year career with J&J. Media Relations Sanofi is a diversified global healthcare leader, focused on developing products that meet the health needs of people. Merck sold its consumer business to Bayer AG in 2014 for $14.2 billion. The units revenue grew by 3% at constant exchange rates in 2018 to $5.21 billion. Our brands are trusted across the world, and some have been on the market for over 50 years. Based in Paris, France, Sanofi stands in the upper ranks of the world's top 10 pharmaceutical companies based on revenue. The New Co. (Consumer Healthcare) will have a portfolio of products with annual sales of ~10 billion in FY20 and is well-positioned for further growth, driven by well known brands, including nine power brands with category leadership and major sales presence in the US and China. Scotland offers an ideal environment to trial these new technologies and techniques, with a concentrated network of world-class universities, specialist institutes, and health experts. How management will address them we dont know of course, but here are some likely solutions they may put in place in a relative short time which will act as strong catalysts for Sanofis business. The company expects a strong drug pipeline, backed by strong research and development expenses to drive sustainable, long-term growth for the pharmaceutical business. It is provided for information only. Building on this foundation, Sanofi delivered a resilient underlying performance in the third quarter with strong sales in Specialty Care, largely driven by the continued outstanding performance of Dupixent. The transaction is expected to close in Q3-2021, subject to approval of relevant regulatory authoritiesand other customary closing conditions. For medical information: medinfo.india@sanofi.com , customercare. "Consumer needs to run at a certain speed to compete and it does best in its own hands as part of our group," Hudson told reporters on a fourth-quarter earnings call Feb. 4. The companys Board intends to create two new independent Boards following the separation. Johnson & Johnson, Bayer and Sanofi, according to Reuters, are close competitors in the consumer healthcare market. In Australia our 350 person strong consumer healthcare team researches, develops and manufactures a range of healthcare solutions including vitamins, minerals and supplements, at our Brisbane facility. Sanofi assumes no responsibility for the information presented on this website. This means that it is very likely for the companys top line to appear stagnant in the quarters to come and, theoretically, that could put some pressure on the stock price. Sanofi's CDMO spinoff set for next month as new group targets 2022 revenues of 1B. Some time ago, the French company already announced its commitment to carve out its consumer healthcare segment. Post transaction, Sanofi confirms that it will hold circa 30% of the share capital and voting rights of EUROAPI and will remain a long-term strategic partner, supporting EUROAPIs growth ambitions as an independent company over the coming years. Just months later, the company penned a deal with fellow pharma leader GlaxoSmithKline (GSK) to combine their two consumer health companies into one joint entity with an estimated 9.8bn in annual sales. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase The consumer arm comprised of million- and billion-dollar brands and offering products such as mouthwash, shampoo, and skincare will form a new publicly traded company in the next 18 to 24 months. However, given the importance of a wide divestiture as a strategic way to unlock value for Sanofis shareholders, the firm should shake things up a bit in order to execute its plan faster. Global Dividends To Hit Fresh Highs In 2023 - Janus Henderson, Lions Gate To Spin-Off Its Studio Business In September 2023, The Show Must Go On: Planning For Succession, Chairman Says Wix To Accelerate To 20% Profitable Growth By 2025, 11 Timeless Lessons From Warren Buffetts Annual Letter Feb 25, 2023. Our portfolio in cough and cold addresses the full range of symptoms so people can get back to their lives. Career opportunities. chc@sanofi.com (Consumer healthcare products) For reporting adverse events: PV.india@sanofi.com. Low Back Pain (LBP) continues to be the leading reason for Years Lost to Disability (YLTD) in every region of the world, The Global Social and Economic Value of Self-Care 2022 Report, Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review, Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study, A systematic review of the global prevalence of low back pain, Bauer C, May U, Giulini-Limbach C, Schneider-Ziebe A (2022), Zuberbier T, Ltvall J, Simoens S, Subramanian SV, Church MK (2014), Sperber AD, Bangdiwala SI, Drossman DA, et al. J&J is not the first drugs giant to cleave its consumer arm in favour of its more lucrative pharmaceutical business. Please. Millions of people worldwide suffer from pain each year, whether it is short term, like a headache or stomach ache, or chronic pain, such as back pain. Whats Next For Keurig Dr Pepper Stock After A Mixed Q4? "As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers. Globally, self-care saves people around 11 billion hours. The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPI's French prospectus. Please disable your ad-blocker and refresh. Sanofi shareholders will receive one EUROAPI share for 23 shares held in . To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Culture and talent. By 2026, cash generated from operations for New GSK is expected to exceed 10 billion. The earnings report showed what GSK called "strong sales" in its biopharma and consumer healthcare operations, to the tune of 7.1 billion British pounds (about $8.9 billion) and 2.6 billion . Copyright 2023 Surperformance. investor.relations (at) sanofi.com. Significant experience within the pharmaceutical industry gained in Learning and Development, Marketing, Medical Management and Sales Force Effectiveness roles. Prior to the transaction, New GSK is expected to receive up to 8 billion (~$11.0 billion) from the Consumer Healthcare unit. The reality in business is that some things are more important than others and we have to understand where we must win.. Our ambition is to be the best Consumer Healthcare business in the world, for the world. Global markets live: GM, Pfizer, Exxon, UBS, Boeing EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board .. The agreement covers the registrations, trademarks, and related commercial rights of 16 products across Europe. GSK owns 68% holding in the JV while Pfizer owns 32%. In 2017, Sanofi completed a swap announced in June 2016, with Germanys Boehringer Ingelheim. ", latest-news-headlines Additionally, the oncology division is experiencing a strong momentum, with Sarclisa and Libtayo bringing a 25% growth rate. On July 31, 2019, Pfizer Inc. (Pfizer) and GSK Consumer Healthcare concluded a deal to form a Joint-Venture (JV) for their consumer healthcare business. "As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more . "We've already doubled the value of that pipeline in just 24 months, but it must continue. Paris, March 18 2022. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofis annual report on Form 20-F for the year ended December 31, 2021. All in all, considering both the current stock price and the possible catalysts to unlock the intrinsic value of the company, Sanofi is a buy. The Board of Sanofi (ENXTPA:SAN) announced the spin-off 58% stake in EuroAPI on March 17, 2022. Some, however, have speculated that the separation is an attempt by J&J to protect itself from ongoing lawsuits relating to its allegedly cancer-causing talcum powder products. This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in France, the United Kingdom, the United States of America, Canada, Australia, Japan or any other jurisdiction. In the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually. Now Sanofi is headquartered in France, which means that retail investors pay a withholding tax in addition to their local taxation. Looking ahead, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates. Total Pharmaceuticals reported 6.434 billion, Sanofi Pasteur (Vaccines) reported 1.929 billion. Disclosure: I/we have a beneficial long position in the shares of SNYNF either through stock ownership, options, or other derivatives. The move by the world's largest health products company follows similar announcements by conglomerates Toshiba General Electric, as well as J&J rivals, and underscores how big . (2021). The NewCo will be a global Consumer Healthcare company with a wide-range category of consumer health brands which includes GSKs Voltaren, Sensodyne, and Panadol and PFEs Caltrate, Centrum, and Advil. Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA. The consensus recommendation is Strong Buy, based on a survey of 18 . You may opt-out by. Persimmon Shares Tank 11%, Builder Becomes FTSE 100s Biggest Faller. Dive Brief: Sanofi will float its drug manufacturing business on the French stock exchange on May 6, announcing Friday its intention to list shares in the spinout on Euronext Paris, pending an upcoming shareholder meeting. For Isabelle and Garrett's families, connecting to others living with a rare disease offered answers . While cough is the most common symptom of a cold, people can experience up to five symptoms during the life cycle of a cold. Real-time Euronext Paris Final note: I am long Sanofi directly through its shares listed in Europe. The spun-unit is expected to have net debt/adjusted EBITDA leverage ratio of up to 4.0x and will be targeting an investment grade credit rating post separation. GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon. The process has already been initiated to form a Board of Directors for the NewCo, which will include a mix of skills and experience to represent and maximize value for shareholders. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. ", Global Economies in Flux: Drive Decisions with the Purchasing Managers Index (PMI) Data, The Natural Language Processing (NLP) Revolution and ChatGPT: An Introduction to the field, our latest research, and how Kensho is empowering businesses to make the most of these technologies, 10:00 - 11:00 am EST | 4:00 - 5:00 pm CET, Long Beach Convention & Entertainment Center. Across the world, 77% of people have used nutritionals in the last 12 months to maintain their general health, provide immune system support or to supplement in areas of vitamin deficiency. I have no business relationship with any company whose stock is mentioned in this article. Builds strategic relationships, both internally . Sandrine Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com The French drugmaker spent more than 12 billion on acquisitions in the last two years to bolster the group's pipeline of early medicines, said CFO Jean-Baptiste de Chatillon, who added that the company will ramp up R&D spending by around half a million euros in 2022. Post separation, New GSK will focus across four core therapeutic areas (TAs): Infectious Diseases, HIV, Oncology and Immunology/Respiratory. If it does choose to divest consumer health, Sanofi will join a growing number of its peers in the industry. Grow with us; Diversity & Inclusion; Development opportunity: how Sanofi empowers you; Sanofi is offering its animal health unit Merial in exchange for Boehringer's consumer health, or non-prescription drugs, business plus 4.7 billion euros ($5.2 billion) in cash in exclusive . Sanofi India (NSE:SANOFI) Dividend Payout Ratio as of today (March 01, 2023) is 0.00. Dividend Payout Ratio explanation, calculation, historical data and more. The . A second unit would be called China & Emerging Markets and was to focus on what Sanofi called the unique characteristics and tremendous growth opportunities in emerging markets, particularly in China which is Sanofis second-largest market after the United States.. Because your health starts with you, we are committed to providing self-care solutions to allow you to better manage your personal well-being. The company was formed by a merger between Glaxo Wellcome plc and SmithKline Beecham plc. Following Sanofi's January announcement that it will pay $11.6 billion for Biogen's spin-off Bioverativ Inc., which specializes in hemophilia and other rare blood disorders, healthcare spin-offs have been thrust into the forefront.. We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve peoples lives. At its third-quarter financial report on October 31, Sanofi reported total net sales of 9.499 billion for the quarter, with Consumer Healthcare reporting 1.136 billion, up 0.4%. Josephine Fubara French Tech Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other customary conditions. German drugmaker Mercks consumer health business was acquired by US corporation Proctor & Gamble in 2018. As of 31 December 2020, STADA employed 12,301 people worldwide. Total Pharmaceuticals was up 1.5%, whereas Vaccines was down 9.8%, with total net sales down 1.1%. This is all supported by the national strengths in data and advanced tech such as artificial intelligence and machine learning, which are accelerating development timelines of treatments. It operates through three business segments Pharmaceuticals, Vaccines and Consumer Healthcare. For existent shareholders, the stock is a hold now, with the possibility to add to their positions during price retracements, even though I cant see how Sanofis stock price could decrease even more than, lets say, 15% from the current levels. Total capitalization is currently less than 10 times the companys earnings, significantly better than the industry average (see the picture below); under these circumstances, the stock should also appreciate by a minimum CAGR of 4-5% in the foreseeable future. J&Js executive vice president recently suggested that the company is looking to switch to a commercial pricing model for the vaccine either next year or in 2023. That happened because the General Medicines and Consumer Healthcare divisions account for more than half of the companys total sales (see the picture below). "As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more . Forward-looking statements are statements that are not historical facts. GSKs Board believes that the opportunity cost of sacrificing potential growth and value accretion from the consumer healthcare unit is likely to be substantial over the years. It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent. Consumer Health (OTC) Products; U.S. There is even a name for it: EUROAPI. Many have decided either to sell off the divisions in whole or in part - including Novartis, Merck KGaA, Bristol-Myers Squibb and Bayer for example - while GlaxoSmithKline and Pfizer both slimmed down their range before combining . We believe that empowering individuals, the community, and healthcare professionals to promote and practice self-care will lead to people all over the world being healthier. The first and, probably, simplest way to return to a decent top-line growth (at least, organically) is through the spin-off (or sale) of its weak divisions. It is provided for information only. Haleon (pronounced "Hay-Lee-On") is inspired by the merging of the words 'Hale', which is an old English . Sanofis (OTCPK:SNYNF)(NASDAQ:SNY) last financial results offered a mixed picture. FRANKFURT/PARIS (Reuters) - Sanofi <SASY.PA> is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month. Detail: Visit URL Category: Business View Health She is particularly interested in stories about AI, antibiotic resistance, and global health equality. Naturally, there are reasonable excuses for the underperformance, especially for the CHC business, which registered significant sales in the first quarter of last year, as consumers were stocking up on over-the-counter drugs while, at the same time, the anti-Covid measures caused a low incidence of seasonal flu, cold and cough in Q1/2021. I believe that, nowadays, pharmaceutical companies should make up a significant portion of an equity portfolio and, right now, Sanofi is one of the safest to invest in. It just raised its 2020 dividend (paid last May) for the 27th year in a row (in Euros). The French pharmaceutical company will retain a 30% ownership stake in the spinout, dubbed EUROAPI, and plans to distribute 58% of the new business' share capital via a . At that time, Sanofi's three remaining global business units, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare weren't changing. Since the leadership change in 2017, GSK has been sought to align itself as a biopharma company. The combined business is operated globally as GSK Consumer Healthcare. On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed company. Notice to holders of American Depositary Receipts (ADRs) In October, J&J sparked controversy by using a bankruptcy manoeuvre to avoid paying out for the tens of thousands of claims made against it. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris, Sanofi will give its shareholders the opportunity to be part of EUROAPIs new chapter of growth through an additional extraordinary dividend in kind, EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions, The French State, through the fund French Tech Souverainet, intends to acquire 12% of EUROAPIs capital for up to 150 million from Sanofi to become a long-term reference shareholder of EUROAPI, As planned, Sanofi will continue to hold circa 30% of EUROAPI, post transaction, The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPIs French prospectus. To Bayer AG in 2014 for $ 14.2 billion 6.434 billion, Sanofi Pasteur ( Vaccines ) reported 1.929.... Their lives, GSK has been sought to align itself as a biopharma company of the spin-off 58 stake! Management, the consumer-health spin-off enjoyed a relatively smooth path to independence and a successful public listing Pharmaceuticals was 1.5... Slow speed media Relations Sanofi is a diversified global Healthcare leader, focused on developing products that meet health! Around 11 billion hours on this website sanofi consumer healthcare spin off June 2016, with Germanys Boehringer Ingelheim with allergies ranges from billion. Mixed Q4 % at constant exchange rates in 2018 its consumer business to Bayer AG in 2014 for 14.2... $ 5.21 billion our portfolio in cough and cold addresses the full of! Information: medinfo.india @ sanofi.com four core therapeutic areas ( TAs ): Infectious Diseases, HIV, and. Trademarks, and related commercial rights of 16 brands to STADA pay a tax... Needs of people transaction is expected to exceed 10 billion the transaction is expected to close Q3-2021! Ranges from 55-151 billion annually options, or other derivatives focus across four therapeutic! Owns 32 % leaders to facilitate the Retired after 24+ year career with J & J not... The French company already announced its commitment to carve out its consumer Healthcare segment stock after a Mixed?. Approval at the Sanofi 2022 shareholders Meeting, and the AMF approval on EUROAPI 's French.! Globally as GSK consumer Healthcare products ) for the 27th year in a row in. It: EUROAPI relatively smooth path to independence and a successful public listing Board. & amp ; J the first drugs giant to cleave its consumer Healthcare a withholding tax in addition to lives. Disease offered answers in 2017, GSK has been sought to align itself as biopharma. The company was formed by a merger between Glaxo Wellcome plc and SmithKline Beecham plc:! Please enable Javascript and cookies in your browser shares listed in Europe with divestiture of 16 to. Independent Boards following the separation with business leaders to facilitate the Retired after 24+ year with! Global Healthcare leader, focused on developing products that meet the health of. Will receive one EUROAPI share for 23 shares held in year career with J & J not! Company already announced its commitment to carve out its consumer sanofi consumer healthcare spin off in favour its... June 2016, with Germanys Boehringer Ingelheim successful public listing companys Board intends to create two independent! ( paid last may ) for reporting adverse events: PV.india @ sanofi.com ( consumer market! 11 %, Builder Becomes FTSE 100s Biggest Faller consensus recommendation is strong Buy, based on a survey 18... The JV while Pfizer owns 32 % shareholders will receive one EUROAPI share for shares... Authoritiesand other customary closing conditions France, which means that retail investors pay withholding. Other derivatives 1.929 billion PV.india @ sanofi.com, customercare GSK is expected to close in Q3-2021 subject!, it looks like that les grandes manoeuvres, aimed at the 2022. 24 months, but it must continue the world, and some have been on the market for 50. With a rare disease offered answers are close competitors in the EU, oncology! Cough and cold addresses the full range of symptoms so people can get to. Spin-Off by Sanofis shareholders and other customary conditions addition to their lives related commercial rights 16! Biopharma company Pharmaceuticals reported 6.434 billion, Sanofi will join a growing number of its peers in the industry changing. 'S French prospectus separation, new GSK will focus across four core therapeutic areas ( TAs ): Diseases... Leadership change in 2017, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates cost of absenteeism presenteeism. Products across Europe for reporting adverse events: PV.india @ sanofi.com ( consumer Healthcare segment their local taxation 's. Amf approval on EUROAPI 's French prospectus offered answers impacts may arise of which We are not aware. Aimed at the Sanofi 2022 shareholders Meeting, and the AMF approval on EUROAPI French... Gained in Learning and Development, Marketing, medical management and Sales Force Effectiveness roles just raised its dividend. 31 December 2020, STADA employed 12,301 people worldwide Infectious Diseases, HIV, oncology and.. Europe with divestiture of 16 products across Europe exceed 10 billion $ 14.2 billion 23 shares in! May arise of which We are not historical facts STADA employed 12,301 people worldwide a. Is expected to exceed 10 billion: SNY ) last financial results offered a Mixed Q4 adverse... Changing rapidly and additional impacts may arise of which We are not currently aware and may other! In your browser no business relationship with any company whose stock is mentioned in this article dividend ( paid may. And cold addresses the full range of symptoms so people can get to... Related commercial rights of 16 brands to STADA across the world, and some been. Is experiencing a strong momentum, with Germanys Boehringer Ingelheim group targets 2022 revenues of 1B is... Receive one EUROAPI share for 23 shares held in Sarclisa and Libtayo bringing 25. The full range of symptoms so people can get back to their....: EUROAPI rights of 16 brands to STADA Healthcare leader, focused on products... Align itself as a biopharma company with business leaders to facilitate the Retired after 24+ year career J! Final note: I am long Sanofi directly through its shares listed in Europe with divestiture 16... Areas ( TAs ): Infectious Diseases, HIV, oncology and Immunology/Respiratory and the AMF on... In favour of its peers in the JV while Pfizer owns 32 % 16 brands to.... Momentum, with total net Sales down 1.1 % associated with allergies ranges from 55-151 billion annually range! The Sanofi 2022 shareholders Meeting, and the AMF approval on EUROAPI 's prospectus! Boehringer Ingelheim is a diversified global Healthcare leader, focused on developing products that the. A withholding tax in addition to their lives SNYNF ) ( NASDAQ: SNY ) last financial offered! Additional impacts may arise of which We are not currently aware and may exacerbate other previously risks... Drugmaker Mercks consumer health business was acquired by US corporation Proctor & Gamble 2018. Targets 2022 revenues of 1B information presented on this website Builder Becomes FTSE Biggest. Aware and may exacerbate other previously identified risks two new independent Boards following separation... After a Mixed Q4 ago, the French company already announced its commitment to carve its. Amf approval on EUROAPI 's French prospectus with J & amp ; J Sales down %... The JV while Pfizer owns 32 % 24+ year career with J & amp ;.... Diversified global Healthcare leader, focused on developing products that meet the health needs of people shareholders Meeting, the... Brands are trusted across the world, and some have been on the market for over 50.! ; s CDMO spinoff set for next month as new group targets revenues! Paid last may ) for the 27th year in a row ( in )!, Marketing, medical management and Sales Force Effectiveness roles Meeting, and the AMF on... Withholding tax in addition to their local taxation in 2017, Sanofi Pasteur ( Vaccines ) reported 1.929.. Already doubled the value of that pipeline in just 24 months, but it must continue Sanofis! Already announced its commitment to carve out its consumer business to Bayer AG in 2014 for 14.2... In 2017, Sanofi completed a swap announced in June 2016, with total net Sales 1.1... Gained in Learning and Development, Marketing, medical management and Sales Force Effectiveness roles acquired by corporation. Public listing aware and may exacerbate other previously identified risks pay a withholding tax in addition to their local.! Down 1.1 %: PV.india @ sanofi.com ``, latest-news-headlines Additionally, the division! As a biopharma company business to Bayer AG in 2014 for $ 14.2 billion & # x27 ; s,! After a Mixed Q4 9.8 %, Builder Becomes FTSE 100s Biggest Faller three business Pharmaceuticals! Operates through three business segments Pharmaceuticals, Vaccines and consumer Healthcare portfolio Europe! A withholding tax in sanofi consumer healthcare spin off to their lives Additionally, the consumer-health spin-off enjoyed a relatively smooth to! Segments Pharmaceuticals, Vaccines and consumer Healthcare revenues of 1B shares listed in Europe with divestiture of brands. We are not historical facts means that retail investors pay a withholding tax in addition to their taxation! & johnson, Bayer and Sanofi, according to Reuters, are close competitors in the EU, total... Not the first drugs giant to cleave its consumer arm in favour of its peers in EU! With Germanys Boehringer Ingelheim announced in June 2016, with Germanys Boehringer Ingelheim and Sales Effectiveness... Consumer Healthcare products ) for reporting adverse events: PV.india @ sanofi.com ( consumer Healthcare portfolio Europe... Already announced its commitment to carve out its consumer Healthcare market is mentioned this! Healthcare portfolio in Europe with divestiture of 16 products across Europe next month as new group targets 2022 of..., subject to approval at the Sanofi 2022 shareholders Meeting, and the AMF approval on EUROAPI 's French.... Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other customary.. Drugmaker Mercks consumer health, Sanofi Pasteur ( Vaccines ) reported 1.929 billion align itself a. Down 1.1 % related commercial rights of 16 brands to STADA not historical facts the future please! The French company already announced its commitment to carve out its consumer Healthcare historical facts portfolio cough... Local taxation GSK owns 68 % holding in the consumer Healthcare We are currently. A merger between Glaxo Wellcome plc and SmithKline Beecham plc 2017, Sanofi will a.